Orthocell Ltd has released a press release.
US Nerve Repair Study Design Meets FDA Requirements
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Orthocell
- SPP Offer Document and Terms And Conditions
- Placement and Share Purchase Plan
- CelGro Nerve Regeneration Results in Quadriplegic Patients
- Successful CelGro Tendon Regeneration Trial
- CelGro Study Validates High Quality Nerve Repair
Later from Orthocell
- Successful CelGro US Bone Repair Study
- CelGro US 510(k) Submission Completed
- Orthocells Ortho-ATI Shows 87.5% Success Rate
- CelGro Nerve Repair AUS Regulatory Application Submitted
- CelGro Bone Regeneration in Dental & Orthopedic Applications
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell